GUTS — Fractyl Health, Inc. Common Stock

Fractyl Health, Inc. Common Stock (GUTS) is a biotechnology company listed on NASDAQ. It is led by Harith Rajagopalan M.D., Ph.D., based in 3 Van de Graaff Drive, Burlington, MA, United States, 01803, with about 109 employees. Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Net income was -$97.2M. GUTS currently screens at market cap $74.9M.

Use this GUTS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GUTS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GUTS SEC filings page. Lician reads the product cache first so this HTML stays unique to Fractyl Health, Inc. Common Stock even when a live quote feed is slow.